HIV-1 induced bystander apoptosis

Viruses

Volumn 4, Issue 11, 2012, Pages 3020-3043

  Garg, Himanshu ^a   Mohl, Jonathon ^a   Joshi, Anjali ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

AIDS; Apoptosis; Bystander; CCR5; Env; Fusion; Gp41; Hemifusion; HIV; Immune activation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; AUTOPHAGY; BYSTANDER EFFECT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE FUSION; NONHUMAN; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SYNCYTIUM; VIRAL TROPISM; VIREMIA; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; APOPTOSIS; AUTOPHAGY; BYSTANDER EFFECT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; RECEPTORS, CCR5; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870626171     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4113020     Document Type: Review

References (149)

1. Hurtrel, B.; Petit, F.; Arnoult, D.; Muller-Trutwin, M.; Silvestri, G.; Estaquier, J. Apoptosis in SIV infection. Cell Death Differ. 2005, 12 (Suppl. 1), 979-990.
2. Silvestri, G. AIDS pathogenesis: A tale of two monkeys. J. Med. Primatol. 2008, 37 (Suppl. 2), 6-12.
3. Gougeon, M.; Montagnier, L. Apoptosis in AIDS. Science 1993, 260, 1269-1270.
4. Laurent-Crawford, A.; Krust, B.; Rivière, Y.; Desgranges, C.; Muller, S.; Kieny, M.; Dauguet, C.; Hovanessian, A. Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Res. Hum. Retroviruses 1993, 9, 761-773.
5. Estaquier, J.; Idziorek, T.; de Bels, F.; Barre-Sinoussi, F.; Hurtrel, B.; Aubertin, A.M.; Venet, A.; Mehtali, M.; Muchmore, E.; Michel, P.; et al. Programmed cell death and AIDS: Significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc. Natl. Acad. Sci. USA 1994, 91, 9431-9435.
6. Finkel, T.; Tudor-Williams, G.; Banda, N.; Cotton, M.; Curiel, T.; Monks, C.; Baba, T.; Ruprecht, R.; Kupfer, A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat. Med. 1995, 1, 129-134.
7. Biard-Piechaczyk, M.; Robert-Hebmann, V.; Richard, V.; Roland, J.; Hipskind, R.; Devaux, C. Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology 2000, 268, 329-344.
8. Ferri, K.F.; Jacotot, E.; Geuskens, M.; Kroemer, G. Apoptosis and karyogamy in syncytia induced by the HIV-1-envelope glycoprotein complex. Cell Death Differ. 2000, 7, 1137-1139.
9. Ahr, B.; Robert-Hebmann, V.; Devaux, C.; Biard-Piechaczyk, M. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004, 1, doi:10.1186/1742-4690-1-12.
10. Gougeon, M. To kill or be killed: How HIV exhausts the immune system. Cell Death Differ. 2005, 12 (Suppl. 1), 845-854.
11. Douek, D.C.; Roederer, M.; Koup, R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 2009, 60, 471-484.
12. Finkel, T.; Banda, N. Indirect mechanisms of HIV pathogenesis: how does HIV kill T cells? Curr. Opin. Immunol. 1994, 6, 605-615.
13. Gougeon, M.; Colizzi, V.; Dalgleish, A.; Montagnier, L. New concepts in AIDS pathogenesis. AIDS Res. Hum. Retroviruses 1993, 9, 287-289.
14. Perfettini, J.; Castedo, M.; Roumier, T.; Andreau, K.; Nardacci, R.; Piacentini, M.; Kroemer, G. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ. 2005, 12 (Suppl. 1), 916-923.
15. Garg, H.; Blumenthal, R. Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell. Mol. Life Sci. 2008, 65, 3134-3144.
16. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998, 280, 1884-1888.
17. Gallo, S.; Finnegan, C.; Viard, M.; Raviv, Y.; Dimitrov, A.; Rawat, S.; Puri, A.; Durell, S.; Blumenthal, R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 2003, 1614, 36-50.
18. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272, 872-877.
19. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272, 1955-1958.
20. Wild, C.; Dubay, J.; Greenwell, T.; Baird, T.J.; Oas, T.; McDanal, C.; Hunter, E.; Matthews, T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA 1994, 91, 12676-12680.
21. Sourisseau, M.; Sol-Foulon, N.; Porrot, F.; Blanchet, F.; Schwartz, O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J. Virol. 2007, 81, 1000-1012.
22. Jolly, C.; Kashefi, K.; Hollinshead, M.; Sattentau, Q. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 2004, 199, 283-293.
23. Jolly, C.; Mitar, I.; Sattentau, Q. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J. Virol. 2007, 81, 13916-13921.
24. Jolly, C.; Sattentau, Q. Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains. J. Virol. 2007, 81, 7873-7884.
25. Jolly, C.; Mitar, I.; Sattentau, Q. Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J. Virol. 2007, 81, 5547-5560.
26. Andreau, K.; Perfettini, J.; Castedo, M.; Métivier, D.; Scott, V.; Pierron, G.; Kroemer, G. Contagious apoptosis facilitated by the HIV-1 envelope: Fusion-induced cell-to-cell transmission of a lethal signal. J. Cell Sci. 2004, 117, 5643-5653.
27. Blanco, J.; Barretina, J.; Henson, G.; Bridger, G.; De Clercq, E.; Clotet, B.; Esté, J. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob. Agents Chemother. 2000, 44, 51-56.
28. Blanco, J.; Barretina, J.; Ferri, K.; Jacotot, E.; Gutiérrez, A.; Armand-Ugón, M.; Cabrera, C.; Kroemer, G.; Clotet, B.; Esté, J. Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. Virology 2003, 305, 318-329.
29. Garg, H.; Joshi, A.; Freed, E.; Blumenthal, R. Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J. Biol. Chem. 2007, 282, 16899-16906.
30. Meissner, E.; Zhang, L.; Jiang, S.; Su, L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J. Virol. 2006, 80, 11019-11030.
31. Doitsh, G.; Cavrois, M.; Lassen, K.G.; Zepeda, O.; Yang, Z.; Santiago, M.L.; Hebbeler, A.M.; Greene, W.C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143, 789-801.
32. Perfettini, J.; Roumier, T.; Castedo, M.; Larochette, N.; Boya, P.; Raynal, B.; Lazar, V.; Ciccosanti, F.; Nardacci, R.; Penninger, J.; et al. NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J. Exp. Med. 2004, 199, 629-640.
33. Spijkerman, I.; de Wolf, F.; Langendam, M.; Schuitemaker, H.; Coutinho, R. Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J. Infect. Dis. 1998, 178, 397-403.
34. Castedo, M.; Kroemer, G. Mitotic catastrophe: A special case of apoptosis. J. Soc. Biol. 2004, 198, 97-103.
35. Roumier, T.; Castedo, M.; Perfettini, J.L.; Andreau, K.; Metivier, D.; Zamzami, N.; Kroemer, G. Mitochondrion-dependent caspase activation by the HIV-1 envelope. Biochem. Pharmacol. 2003, 66, 1321-1329.
36. Castedo, M.; Perfettini, J.L.; Roumier, T.; Valent, A.; Raslova, H.; Yakushijin, K.; Horne, D.; Feunteun, J.; Lenoir, G.; Medema, R.; et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004, 23, 4362-4370.
37. Castedo, M.; Perfettini, J.L.; Roumier, T.; Yakushijin, K.; Horne, D.; Medema, R.; Kroemer, G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004, 23, 4353-4361.
38. Castedo, M.; Ferri, K.F.; Blanco, J.; Roumier, T.; Larochette, N.; Barretina, J.; Amendola, A.; Nardacci, R.; Metivier, D.; Este, J.A.; et al. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J. Exp. Med. 2001, 194, 1097-1110.
39. Ferri, K.F.; Kroemer, G. Control of apoptotic DNA degradation. Nat. Cell Biol. 2000, 2, E63-E64.
40. Ferri, K.F.; Jacotot, E.; Blanco, J.; Este, J.A.; Zamzami, N.; Susin, S.A.; Xie, Z.; Brothers, G.; Reed, J.C.; Penninger, J.M.; et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: Role of mitochondria and caspases. J. Exp. Med. 2000, 192, 1081-1092.
41. Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626-629.
42. Castedo, M.; Roumier, T.; Blanco, J.; Ferri, K.F.; Barretina, J.; Tintignac, L.A.; Andreau, K.; Perfettini, J.L.; Amendola, A.; Nardacci, R.; et al. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. 2002, 21, 4070-4080.
43. Perfettini, J.L.; Castedo, M.; Nardacci, R.; Ciccosanti, F.; Boya, P.; Roumier, T.; Larochette, N.; Piacentini, M.; Kroemer, G. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J. Exp. Med. 2005, 201, 279-289.
44. Cannavo, G.; Paiardini, M.; Galati, D.; Cervasi, B.; Montroni, M.; De Vico, G.; Guetard, D.; Bocchino, M.L.; Picerno, I.; Magnani, M.; et al. Abnormal intracellular kinetics of cell-cycle-dependent proteins in lymphocytes from patients infected with human immunodeficiency virus: A novel biologic link between immune activation, accelerated T-cell turnover, and high levels of apoptosis. Blood 2001, 97, 1756-1764.
45. Piedimonte, G.; Corsi, D.; Paiardini, M.; Cannavo, G.; Ientile, R.; Picerno, I.; Montroni, M.; Silvestri, G.; Magnani, M. Unscheduled cyclin B expression and p34 cdc2 activation in T lymphocytes from HIV-infected patients. AIDS 1999, 13, 1159-1164.
46. Murooka, T.T.; Deruaz, M.; Marangoni, F.; Vrbanac, V.D.; Seung, E.; von Andrian, U.H.; Tager, A.M.; Luster, A.D.; Mempel, T.R. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490, 283-287.
47. Chernomordik, L.; Kozlov, M. Membrane hemifusion: Crossing a chasm in two leaps. Cell 2005, 123, 375-382.
48. Bar, S.; Alizon, M. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J. Virol. 2004, 78, 811-820.
49. Wang, X.M.; Nadeau, P.E.; Lo, Y.T.; Mergia, A. Caveolin-1 modulates HIV-1 envelope-induced bystander apoptosis through gp41. J. Virol. 2010, 84, 6515-6526.
50. Garg, H.; Blumenthal, R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J. Leukoc. Biol. 2006, 79, 351-362.
51. Ashkenazi, A.; Viard, M.; Wexler-Cohen, Y.; Blumenthal, R.; Shai, Y. Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J. 2011, 25, 2156-2166.
52. Barretina, J.; Blanco, J.; Armand-Ugon, M.; Gutierrez, A.; Clotet, B.; Este, J.A. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir. Ther. 2003, 8, 155-161.
53. Cunyat, F.; Curriu, M.; Marfil, S.; Garcia, E.; Clotet, B.; Blanco, J.; Cabrera, C. Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines. J. Biomol. Screen. 2012, 17, 727-737.
54. Etemad-Moghadam, B.; Rhone, D.; Steenbeke, T.; Sun, Y.; Manola, J.; Gelman, R.; Fanton, J.; Racz, P.; Tenner-Racz, K.; Axthelm, M.; et al. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J. Virol. 2001, 75, 5646-5655.
55. Etemad-Moghadam, B.; Sun, Y.; Nicholson, E.; Fernandes, M.; Liou, K.; Gomila, R.; Lee, J.; Sodroski, J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 2000, 74, 4433-4440.
56. Koot, M.; van 't Wout, A.; Kootstra, N.; de Goede, R.; Tersmette, M.; Schuitemaker, H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 1996, 173, 349-354.
57. Schuitemaker, H.; Koot, M.; Kootstra, N.; Dercksen, M.; de Goede, R.; van Steenwijk, R.; Lange, J.; Schattenkerk, J.; Miedema, F.; Tersmette, M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 1992, 66, 1354-1360.
58. van Rij, R.P.; Blaak, H.; Visser, J.; Brouwer, M.; Rientsma, R.; Broersen, S.; de Roda Husman, A.M.; Schuitemaker, H. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J. Clin. Invest. 2000, 106, 1569.
59. Garg, H.; Joshi, A.; Ye, C.; Shankar, P.; Manjunath, N. Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virol. J. 2011, 8, doi:10.1186/1743-422X-8-34.
60. Jekle, A.; Keppler, O.; De Clercq, E.; Schols, D.; Weinstein, M.; Goldsmith, M. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Virol. 2003, 77, 5846-5854.
61. Anton, P.A.; Elliott, J.; Poles, M.A.; McGowan, I.M.; Matud, J.; Hultin, L.E.; Grovit-Ferbas, K.; Mackay, C.R.; Chen, I.S.Y.; Giorgi, J.V. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000, 14, 1761-1765.
62. Mehandru, S.; Poles, M.A.; Tenner-Racz, K.; Horowitz, A.; Hurley, A.; Hogan, C.; Boden, D.; Racz, P.; Markowitz, M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200, 761-770.
63. Sterjovski, J.; Churchill, M.J.; Ellett, A.; Gray, L.R.; Roche, M.J.; Dunfee, R.L.; Purcell, D.F.; Saksena, N.; Wang, B.; Sonza, S.; et al. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 2007, 4, doi:10.1186/1742-4690-4-89.
64. Holm, G.; Zhang, C.; Gorry, P.; Peden, K.; Schols, D.; De Clercq, E.; Gabuzda, D. Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J. Virol. 2004, 78, 4541-4551.
65. Wade, J.; Sterjovski, J.; Gray, L.; Roche, M.; Chiavaroli, L.; Ellett, A.; Jakobsen, M.R.; Cowley, D.; Pereira Cda, F.; Saksena, N.; et al. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology 396, 246-255.
66. Olivieri, K.; Scoggins, R.; Bor, Y.; Matthews, A.; Mark, D.; Taylor, J.J.; Chernauskas, D.; Hammarskjöld, M.; Rekosh, D.; Camerini, D. The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. Virology 2007, 358, 23-38.
67. Bjorndal, A.; Sonnerborg, A.; Tscherning, C.; Albert, J.; Fenyo, E.M. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res. Hum. Retroviruses 1999, 15, 647-653.
68. Edo-Matas, D.; van Dort, K.A.; Setiawan, L.C.; Schuitemaker, H.; Kootstra, N.A. Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology 2011, 412, 269-277.
69. Huang, W.; Eshleman, S.H.; Toma, J.; Fransen, S.; Stawiski, E.; Paxinos, E.E.; Whitcomb, J.M.; Young, A.M.; Donnell, D.; Mmiro, F.; et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 2007, 81, 7885-7893.
70. Coetzer, M.; Nedellec, R.; Cilliers, T.; Meyers, T.; Morris, L.; Mosier, D.E. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J. Acquir. Immune Defic. Syndr. 2011, 56, 9-15.
71. Ng, O.T.; Lin, L.; Laeyendecker, O.; Quinn, T.C.; Sun, Y.J.; Lee, C.C.; Leo, Y.S. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore. PLoS One 2011, 6, e15738.
72. Dean, M.; Carrington, M.; Winkler, C.; Huttley, G.A.; Smith, M.W.; Allikmets, R.; Goedert, J.J.; Buchbinder, S.P.; Vittinghoff, E.; Gomperts, E.; et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273, 1856-1862.
73. Liu, R.; Paxton, W.; Choe, S.; Ceradini, D.; Martin, S.; Horuk, R.; MacDonald, M.; Stuhlmann, H.; Koup, R.; Landau, N. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86, 367-377.
74. Marmor, M.; Sheppard, H.; Donnell, D.; Bozeman, S.; Celum, C.; Buchbinder, S.; Koblin, B.; Seage, G.R. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J. Acquir. Immune Defic. Syndr. 2001, 27, 472-481.
75. de Roda Husman, A.M.; Koot, M.; Cornelissen, M.; Keet, I.P.; Brouwer, M.; Broersen, S.M.; Bakker, M.; Roos, M.T.; Prins, M.; de Wolf, F.; et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 1997, 127, 882-890.
76. Ometto, L.; Bertorelle, R.; Mainardi, M.; Zanchetta, M.; Tognazzo, S.; Rampon, O.; Ruga, E.; Chieco-Bianchi, L.; De Rossi, A. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J. Infect. Dis. 2001, 183, 814-818.
77. Shieh, B.; Liau, Y.; Hsieh, P.; Yan, Y.; Wang, S.; Li, C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int. Immunol. 2000, 12, 1311-1318.
78. Reeves, J.; Gallo, S.; Ahmad, N.; Miamidian, J.; Harvey, P.; Sharron, M.; Pohlmann, S.; Sfakianos, J.; Derdeyn, C.; Blumenthal, R.; et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 2002, 99, 16249-16254.
79. Wu, L.; Paxton, W.A.; Kassam, N.; Ruffing, N.; Rottman, J.B.; Sullivan, N.; Choe, H.; Sodroski, J.; Newman, W.; Koup, R.A.; et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185, 1681-1691.
80. Scoggins, R.; Taylor, J.J.; Patrie, J.; van't Wout, A.; Schuitemaker, H.; Camerini, D. Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J. Virol. 2000, 74, 3205-3216.
81. Paiardini, M.; Cervasi, B.; Reyes-Aviles, E.; Micci, L.; Ortiz, A.M.; Chahroudi, A.; Vinton, C.; Gordon, S.N.; Bosinger, S.E.; Francella, N.; et al. Low levels of SIV infection in sooty mangabey central memory CD(4)(+) T cells are associated with limited CCR5 expression. Nat. Med. 2011, 17, 830-836.
82. Platt, E.; Wehrly, K.; Kuhmann, S.; Chesebro, B.; Kabat, D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72, 2855-2864.
83. Platt, E.; Durnin, J.; Kabat, D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 2005, 79, 4347-4356.
84. Joshi, A.; Nyakeriga, A.M.; Ravi, R.; Garg, H. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. J. Biol. Chem. 2011, 286, 36404-36413.
85. Schmid, D.; Munz, C. Innate and adaptive immunity through autophagy. Immunity 2007, 27, 11-21.
86. Schmid, D.; Pypaert, M.; Munz, C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 2007, 26, 79-92.
87. Espert, L.; Biard-Piechaczyk, M. Autophagy in HIV-induced T cell death. Curr. Top. Microbiol. Immunol. 2009, 335, 307-321.
88. Espert, L.; Varbanov, M.; Robert-Hebmann, V.; Sagnier, S.; Robbins, I.; Sanchez, F.; Lafont, V.; Biard-Piechaczyk, M. Differential role of autophagy in CD4 T cells and macrophages during X4 and R5 HIV-1 infection. PLoS One 2009, 4, e5787.
89. Spector, S.A.; Zhou, D. Autophagy: An overlooked mechanism of HIV-1 pathogenesis and neuroAIDS? Autophagy 2008, 4, 704-706.
90. Deretic, V. Autophagy as an immune defense mechanism. Curr. Opin. Immunol. 2006, 18, 375-382.
91. Deretic, V. Autophagy of intracellular microbes and mitochondria: Two sides of the same coin? F1000 Biol. Rep. 2010, 2, doi:10.3410/B2-45.
92. Deretic, V. Autophagy in infection. Curr. Opin. Cell Biol. 2010, 22, 252-262.
93. Kyei, G.B.; Dinkins, C.; Davis, A.S.; Roberts, E.; Singh, S.B.; Dong, C.; Wu, L.; Kominami, E.; Ueno, T.; Yamamoto, A.; et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J. Cell Biol. 2009, 186, 255-268.
94. McCarroll, S.A.; Huett, A.; Kuballa, P.; Chilewski, S.D.; Landry, A.; Goyette, P.; Zody, M.C.; Hall, J.L.; Brant, S.R.; Cho, J.H.; et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat. Genet. 2008, 40, 1107-1112.
95. Gregoire, I.P.; Richetta, C.; Meyniel-Schicklin, L.; Borel, S.; Pradezynski, F.; Diaz, O.; Deloire, A.; Azocar, O.; Baguet, J.; Le Breton, M.; et al. IRGM is a common target of RNA viruses that subvert the autophagy network. PLoS Pathog. 2011, 7, e1002422.
96. Espert, L.; Denizot, M.; Grimaldi, M.; Robert-Hebmann, V.; Gay, B.; Varbanov, M.; Codogno, P.; Biard-Piechaczyk, M. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J. Clin. Invest. 2006, 116, 2161-2172.
97. Denizot, M.; Varbanov, M.; Espert, L.; Robert-Hebmann, V.; Sagnier, S.; Garcia, E.; Curriu, M.; Mamoun, R.; Blanco, J.; Biard-Piechaczyk, M. HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy 2008, 4, 998-1008.
98. Scherz-Shouval, R.; Shvets, E.; Fass, E.; Shorer, H.; Gil, L.; Elazar, Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007, 26, 1749-1760.
99. Gougeon, M.L.; Piacentini, M. New insights on the role of apoptosis and autophagy in HIV pathogenesis. Apoptosis 2009, 14, 501-508.
100. Wild, C.; Shugars, D.; Greenwell, T.; McDanal, C.; Matthews, T. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 1994, 91, 9770-9774.
101. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P.; et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004, 18, 1787-1794.
102. Reeves, J.; Lee, F.; Miamidian, J.; Jabara, C.; Juntilla, M.; Doms, R. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 2005, 79, 4991-4999.
103. Barretina, J.; Blanco, J.; Bonjoch, A.; Llano, A.; Clotet, B.; Esté, J. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004, 18, 1673-1682.
104. Bonora, S.; Calcagno, A.; Cometto, C.; Fontana, S.; Aguilar, D.; D'Avolio, A.; Gonzalez de Requena, D.; Maiello, A.; Dal Conte, I.; Lucchini, A.; et al. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: A controlled pilot study. Infection 2012, 40, 69-75.
105. Aquaro, S.; D'Arrigo, R.; Svicher, V.; Perri, G.; Caputo, S.; Visco-Comandini, U.; Santoro, M.; Bertoli, A.; Mazzotta, F.; Bonora, S.; et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 2006, 58, 714-722.
106. Melby, T.; Despirito, M.; Demasi, R.; Heilek, G.; Thommes, J.; Greenberg, M.; Graham, N. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007, 21, 2537-2539.
107. Svicher, V.; Aquaro, S.; D'Arrigo, R.; Artese, A.; Dimonte, S.; Alcaro, S.; Santoro, M.; Di Perri, G.; Caputo, S.; Bellagamba, R.; et al. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J. Infect. Dis. 2008, 197, 1408-1418.
108. Garg, H.; Joshi, A.; Blumenthal, R. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. AIDS Res. Hum. Retroviruses 2009, 25, 811-817.
109. Cunyat, F.; Marfil, S.; Garcia, E.; Svicher, V.; Perez-Alvarez, N.; Curriu, M.; Perno, C.F.; Clotet, B.; Blanco, J.; Cabrera, C. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. Retrovirology 2012, 9, doi:10.1186/1742-4690-9-15.
110. Bentwich, Z.; Kalinkovich, A.; Weisman, Z.; Grossman, Z. Immune activation in the context of HIV infection. Clin. Exp. Immunol. 1998, 111, 1-2.
111. Sodora, D.; Silvestri, G. Immune activation and AIDS pathogenesis. AIDS 2008, 22, 439-446.
112. Estes, J.; Gordon, S.; Zeng, M.; Chahroudi, A.; Dunham, R.; Staprans, S.; Reilly, C.; Silvestri, G.; Haase, A. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J. Immunol. 2008, 180, 6798-6807.
113. Silvestri, G.; Sodora, D.; Koup, R.; Paiardini, M.; O'Neil, S.; McClure, H.; Staprans, S.; Feinberg, M. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18, 441-452.
114. Grossman, Z.; Meier-Schellersheim, M.; Paul, W.; Picker, L. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat. Med. 2006, 12, 289-295.
115. Grossman, Z.; Meier-Schellersheim, M.; Sousa, A.; Victorino, R.; Paul, W. CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat. Med. 2002, 8, 319-323.
116. Al-Harthi, L.; MaWhinney, S.; Connick, E.; Schooley, R.; Forster, J.; Benson, C.; Thompson, M.; Judson, F.; Palella, F.; Landay, A. Immunophenotypic alterations in acute and early HIV infection. Clin. Immunol. 2007, 125, 299-308.
117. Biancotto, A.; Grivel, J.; Iglehart, S.; Vanpouille, C.; Lisco, A.; Sieg, S.; Debernardo, R.; Garate, K.; Rodriguez, B.; Margolis, L.; et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007, 109, 4272-4279.
118. Gougeon, M. T cell apoptosis as a consequence of chronic activation of the immune system in HIV infection. Adv. Exp. Med. Biol. 1995, 374, 121-127.
119. Leng, Q.; Borkow, G.; Weisman, Z.; Stein, M.; Kalinkovich, A.; Bentwich, Z. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J. Acquir. Immune Defic. Syndr. 2001, 27, 389-397.
120. Sousa, A.; Carneiro, J.; Meier-Schellersheim, M.; Grossman, Z.; Victorino, R. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 2002, 169, 3400-3406.
121. Resino, S.; Seoane, E.; Gutiérrez, M.; León, J.; Muñoz-Fernández, M. CD4(+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2006, 42, 269-276.
122. Biancotto, A.; Iglehart, S.; Vanpouille, C.; Condack, C.; Lisco, A.; Ruecker, E.; Hirsch, I.; Margolis, L.; Grivel, J. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008, 111, 699-704.
123. Koning, F.; Otto, S.; Hazenberg, M.; Dekker, L.; Prins, M.; Miedema, F.; Schuitemaker, H. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol. 2005, 175, 6117-6122.
124. Kaufmann, G.; Zaunders, J.; Cooper, D. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex. Transm. Infect. 1999, 75, 218-224.
125. Brenchley, J.; Price, D.; Schacker, T.; Asher, T.; Silvestri, G.; Rao, S.; Kazzaz, Z.; Bornstein, E.; Lambotte, O.; Altmann, D.; et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006, 12, 1365-1371.
126. Redd, A.D.; Gray, R.H.; Quinn, T.C. Is microbial translocation a cause or consequence of HIV disease progression? J. Infect. Dis. 2011, 203, 744-745; author reply 746.
127. Brainard, D.M.; Seung, E.; Frahm, N.; Cariappa, A.; Bailey, C.C.; Hart, W.K.; Shin, H.S.; Brooks, S.F.; Knight, H.L.; Eichbaum, Q.; et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 2009, 83, 7305-7321.
128. Ameisen, J.C.; Capron, A. Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol. Today 1991, 12, 102-105.
129. Lecoeur, H.; Gougeon, M.L. Comparative analysis of flow cytometric methods for apoptosis quantitation in murine thymocytes and human peripheral lymphocytes from controls and HIV-infected persons. Evidence for interference by granulocytes and erythrocytes. J. Immunol. Methods 1996, 198, 87-99.
130. Peraire, J.; Miro, O.; Saumoy, M.; Domingo, P.; Pedrol, E.; Villarroya, F.; Martinez, E.; Lopez-Dupla, M.; Garrabou, G.; Sambeat, M.A.; et al. HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr. HIV Res. 2007, 5, 467-473.
131. Sternfeld, T.; Tischleder, A.; Schuster, M.; Bogner, J.R. Mitochondrial membrane potential and apoptosis of blood mononuclear cells in untreated HIV-1 infected patients. HIV Med. 2009, 10, 512-519.
132. Badley, A.; Roumier, T.; Lum, J.; Kroemer, G. Mitochondrion-mediated apoptosis in HIV-1 infection. Trends Pharmacol. Sci. 2003, 24, 298-305.
133. de Oliveira Pinto, L.M.; Garcia, S.; Lecoeur, H.; Rapp, C.; Gougeon, M.L. Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)-and TNFR2-mediated apoptosis in HIV infection: Relation to expression of Bcl-2 and active caspase-8 and caspase-3. Blood 2002, 99, 1666-1675.
134. Rey-Cuille, M.A.; Berthier, J.L.; Bomsel-Demontoy, M.C.; Chaduc, Y.; Montagnier, L.; Hovanessian, A.G.; Chakrabarti, L.A. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J. Virol. 1998, 72, 3872-3886.
135. Chakrabarti, L.A.; Lewin, S.R.; Zhang, L.; Gettie, A.; Luckay, A.; Martin, L.N.; Skulsky, E.; Ho, D.D.; Cheng-Mayer, C.; Marx, P.A. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J. Virol. 2000, 74, 1209-1223.
136. Cumont, M.C.; Diop, O.; Vaslin, B.; Elbim, C.; Viollet, L.; Monceaux, V.; Lay, S.; Silvestri, G.; Le Grand, R.; Muller-Trutwin, M.; et al. Early divergence in lymphoid tissue apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates. J. Virol. 2008, 82, 1175-1184.
137. Meythaler, M.; Martinot, A.; Wang, Z.; Pryputniewicz, S.; Kasheta, M.; Ling, B.; Marx, P.A.; O'Neil, S.; Kaur, A. Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection. J. Virol. 2009, 83, 572-583.
138. Meythaler, M.; Pryputniewicz, S.; Kaur, A. Kinetics of T lymphocyte apoptosis and the cellular immune response in SIVmac239-infected rhesus macaques. J. Med. Primatol. 2008, 37 (Suppl. 2), 33-45.
139. Reimann, K.A.; Li, J.T.; Veazey, R.; Halloran, M.; Park, I.W.; Karlsson, G.B.; Sodroski, J.; Letvin, N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 1996, 70, 6922-6928.
140. Karlsson, G.B.; Halloran, M.; Li, J.; Park, I.W.; Gomila, R.; Reimann, K.A.; Axthelm, M.K.; Iliff, S.A.; Letvin, N.L.; Sodroski, J. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J. Virol. 1997, 71, 4218-4225.
141. Karlsson, G.; Halloran, M.; Schenten, D.; Lee, J.; Racz, P.; Tenner-Racz, K.; Manola, J.; Gelman, R.; Etemad-Moghadam, B.; Desjardins, E.; et al. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J. Exp. Med. 1998, 188, 1159-1171.
142. LaBonte, J.; Patel, T.; Hofmann, W.; Sodroski, J. Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J. Virol. 2000, 74, 10690-10698.
143. Berges, B.K.; Rowan, M.R. The utility of the new generation of humanized mice to study HIV-1 infection: Transmission, prevention, pathogenesis, and treatment. Retrovirology 2011, 8, doi:10.1186/1742-4690-8-65.
144. -/- (RAG-hu) mouse model. Retrovirology 2006, 3, doi:10.1186/1742-4690-3-76.
145. Shultz, L.; Lang, P.; Christianson, S.; Gott, B.; Lyons, B.; Umeda, S.; Leiter, E.; Hesselton, R.; Wagar, E.; Leif, J.; et al. NOD/LtSz-Rag1null mice: An immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J. Immunol. 2000, 164, 2496-2507.
146. Zhang, L.; Kovalev, G.; Su, L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007, 109, 2978-2981.
147. -/- mice. Proc. Natl. Acad. Sci. USA 2006, 103, 15951-15956.
148. Camerini, D.; Su, H.; Gamez-Torre, G.; Johnson, M.; Zack, J.; Chen, I. Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication. J. Virol. 2000, 74, 3196-3204.
149. Joshi, A.; Garg, H.; Ablan, S.; Freed, E.O.; Nagashima, K.; Manjunath, N.; Shankar, P. Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology 2011, 415, 95-106.